Landiolol hydrochloride freeze-dried powder injection for injection and preparation method thereof

By adjusting the ratio and pH value of lyophilized hydrochloride to mannitol, combined with strict lyophilized temperature control, the stability and temperature resistance of lyophilized hydrochloride powder needles are solved, achieving efficient and safe The preparation process improves the storage period and safety of the drug.

CN118986903APending Publication Date: 2024-11-22HEBEI YIPIN BIOPHARMACEUTICAL CO LTD
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411254532.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-09
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

The existing preparation process of lyophilized lyophilized powder needles with poor stability, and the finished product is not resistant to high temperature, which affects its storage and use safety.

Method used

The mass ratio of lycodiluol hydrochloride to mannitol is 1:0.8~1:1.2, and the pH value is adjusted to 6.1±0.1 using a 0.05 mol/L sodium hydroxide solution, and the temperature of the lyophilization step and the vacuum drying conditions are controlled. Ensure temperature control and pH stability of the preparation process.

Benefits of technology

It improves the stability and storage period of lyophilized lyophilized powder needles of lyophilized lyophilized powder needles, ensures high purity, low total miscellaneousness, good resolubility, and is suitable for industrial production and clinical use.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

The invention provides a landiolol hydrochloride freeze-dried powder injection for injection, which comprises landiolol hydrochloride, mannitol and a pH regulator, and the pH regulator is a sodium hydroxide solution with the concentration of 0.05 mol / L. The preparation product disclosed by the invention is good in appearance property, high in purity, low in total impurity content, stable in quality, not easy to deteriorate, and easy to store and transport. The invention also provides a preparation method of the landiolol hydrochloride freeze-dried powder injection for injection, which comprises the following steps: S1, liquid preparation: dissolving mannitol by using part of water for injection, adding landiolol hydrochloride, continuously stirring and dissolving, regulating the pH value to 6.1 + / -0.1 by using the pH regulator, and supplementing the whole amount of water for injection; after filtering, filling to prepare an injection, and feeding the injection into a freeze-drying box after semi-plugging; and S2, freeze-drying: pre-freezing in a freeze-drying box, keeping the temperature when the temperature of the product is reduced to-45 DEG C or below, starting a vacuum pump to carry out sublimation drying, pressing a plug and taking out of the box after drying is finished, and thus obtaining the product. The preparation process is simple and feasible, avoids the increase of total impurities in the preparation process, and is suitable for large-scale industrial production.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of pharmaceuticals, and in particular to a freeze-dried powder injection of landiolol hydrochloride for injection and a preparation method thereof. Background Art

[0002] Landiolol hydrochloride is an ultra-short-acting adrenergic β-receptor blocker. Landiolol hydrochloride mainly antagonizes the β1 receptors present in the heart, and improves tachycardia arrhythmias by inhibiting the increase in heart rate caused by catecholamines; it is mainly used clinically for the emergency treatment of tachycardia arrhythmias (including atrial fibrillation, atrial flutter, and sinus tachycardia) during surgery, and for the emergency treatment of tachycardia arrhythmias (including atrial flutter, atrial fibrillation, and sinus tachycardia) under postoperative circulatory dynamic monitoring.

[0003] At present, the only ultra-short-acting adrenergic beta-receptor blocker drug on the market is esmolol hydrochloride, which has been on the market for more than 20 years. Compared with esmolol hydrochloride, landiolol hydrochloride has higher cardiac receptor selectivity, less hypotensive side effects, more rapid onset, shorter duration of action, weaker cardiac transplant rejection, fewer contraindications, and higher safety. It has great clinical advantages and is expected to gradually replace esmolol hydrochloride in the future. At present, the original research of landiolol hydrochloride for injection has not been registered for import in China, and only the preparation of Nanjing Haichen Pharmaceutical Co., Ltd. is on the market in China.

[0004] On August 31, 2016, Chenxin Pharmaceutical Co., Ltd. applied for a landiolol hydrochloride lyophilized powder injection and its preparation process (application number 201610792311.5). The specific steps of the preparation process are: dissolve mannitol with partially boiled water for injection, cool below 60°C, add landiolol hydrochloride and stir to dissolve, adjust the pH value with a pH regulator to add water for injection to the full amount, add activated carbon and stir to adsorb, filter, fill, and freeze-dry. The invention is developed based on the various physical and chemical properties of landiolol hydrochloride. The landiolol hydrochloride lyophilized powder injection has a fast onset of action, is safe to use, has a stable preparation, and has good water solubility. The preparation process is simple, easy, and suitable for large-scale industrial production. However, in actual preparation and use, it was found that the process not only has poor stability during the preparation process, but also the finished product cannot tolerate high temperatures, and further improvement and optimization are needed to improve the stability of the preparation. Summary of the invention

[0005] The object of the present invention is to provide a lyophilized powder of landiolol hydrochloride for injection with good stability and long-term storage and a preparation method thereof in view of the drawbacks of the prior art.

[0006] The technical solution adopted by the present invention to solve its technical problem is:

[0007] A landiolol hydrochloride lyophilized powder for injection comprises landiolol hydrochloride, mannitol, and a pH regulator, wherein the mass ratio of the landiol hydrochloride to the mannitol is 1:0.8 to 1:1.2, preferably 1:1. The pH regulator is a sodium hydroxide solution with a concentration of 0.05 mol / L.

[0008] Each vial of landiolol hydrochloride injection contains 50 mg of the main drug landiol hydrochloride.

[0009] A method for preparing landiolol hydrochloride lyophilized powder for injection comprises the following steps:

[0010] S1. Liquid preparation

[0011] Dissolve the prescribed amount of mannitol with part of the injection water, add the prescribed amount of landiolol hydrochloride and continue stirring to dissolve, adjust the pH value to 6.1±0.1 with a pH adjuster, and add the full amount of injection water; filter and fill the injection, and send it into a freeze-drying box after half-stoppering;

[0012] S2. Freeze-drying

[0013] The freeze-drying box is pre-freezing, and the product temperature is kept below -45°C, and the vacuum pump is started for primary and secondary drying. After drying, the plug is pressed out of the box to obtain the landiolol hydrochloride lyophilized powder for injection.

[0014] The step S1 specifically includes the following steps:

[0015] S11, dissolving mannitol with 80% of the prescribed amount of water for injection, controlling the temperature at 10-25° C., to obtain solution I;

[0016] S12, adding landiolol hydrochloride to solution I to dissolve, controlling the temperature at 10-25° C., to obtain solution II;

[0017] S13, adjust the pH value of solution II to 6.1±0.1 with 0.05 mol / L sodium hydroxide solution, stir for 10±2 min, add full amount of water for injection, and after stirring, filter with a 0.45 μm microporous filter and then fine filter with a 0.22 μm microporous filter to obtain solution III;

[0018] S14. Fill solution III into a 10 ml neutral silicone tube injection bottle, half-stopper it with a rubber stopper, and then send it into the freeze-drying box.

[0019] The liquid preparation temperature in step S1 does not exceed 25° C.; the rubber stopper is an ethylene tetrafluoroethylene copolymer film chlorinated butyl rubber stopper.

[0020] The step S2 specifically includes the following steps:

[0021] S21, pre-freezing

[0022] Install solution III in the machine for pre-freezing, set the refrigeration temperature of the partition to -45°C, keep the product temperature below -45°C, and then refrigerate the water trap to -45°C±1°C; turn on the vacuum pump, and start heating and sublimation when the vacuum degree in the freeze-drying box reaches 20Pa;

[0023] S22, one-step drying

[0024] Set the partition temperature to -15°C and start heating sublimation; after the partition temperature reaches -15°C, continue drying at this temperature for 15 to 45 hours;

[0025] S23, one-step drying

[0026] Set the partition temperature to 45°C, continue heating to remove bound water, and continue to keep warm and dry for 2 to 6 hours after reaching 45°C;

[0027] S24, full pressure plug

[0028] After the product is freeze-dried, fill the box with nitrogen to -0.04MPa~-0.01MPa, turn off the nitrogen, balance for 10 minutes, and then press the full plug button to start the full plug process. Repeat the plugging twice, raise the shelf, open the freeze dryer air valve to balance the pressure of the box to normal pressure, and start unpacking.

[0029] During the primary drying, the partition temperature rises from -45°C to -15°C within 60 minutes; during the secondary drying, the partition temperature rises from -15°C to 45°C within 120 minutes.

[0030] During the secondary drying process, the vacuum is controlled at 10Pa to 30Pa by means of air permeation.

[0031] Through the above technical solution, the beneficial effects obtained by the present invention are:

[0032] The invention provides a lyophilized powder of landiolol hydrochloride for injection, which has good appearance, high purity, low total impurities, stable quality and is not easy to deteriorate. The preparation is loose and has good resolubility, and is easy to store and transport. The preparation has rapid drug effect, is safe and reliable to use, and meets the relevant requirements of the pharmacopoeia.

[0033] The present invention also provides a method for preparing a lyophilized powder of landiolol hydrochloride for injection, wherein the preparation parameters are improved and controlled according to the properties of landiolol hydrochloride, and the preparation steps, the temperature in the dissolution / lyophilization process, the pH control node and other parameters are defined in detail to avoid the increase of total impurities in the preparation process, thereby ensuring the stable quality of the preparation. The preparation process is simple and easy to implement, and is suitable for large-scale industrial production.

[0034] The present invention clearly limits the end point pH value of the preparation to 6.1±0.1. Experiments have shown that both too high and too low pH values ​​are not conducive to long-term storage, especially when pH <5.3 or pH>6.8, the product impurities increase significantly; when the pH value is within the range of 5.5 to 6.5, the pH range is too large, which will lead to unstable total impurity content and is not conducive to product quality control. Therefore, the present invention specifically limits the pH value to 6.1 and only gives a variation range of ±0.1, which can minimize the generation of impurities, ensure the stability of the content and total impurities of the freeze-dried powder injection product, effectively extend its shelf life, and improve product quality control.

[0035] In the freeze-drying step of the present invention, the primary drying temperature is controlled at -15°C. Compared with the primary drying temperature of -5°C in the prior art, the lower temperature can effectively prevent partial melting of the product, improve the product shape of the freeze-dried powder injection, make it looser, and facilitate re-dissolution in water. Both the primary drying and secondary drying processes adopt constant temperature drying, without step-by-step heating and frequent operation, which is conducive to industrial control. DETAILED DESCRIPTION

[0036] The technical solution of the present invention will be clearly and completely described below in conjunction with specific embodiments. Obviously, the described embodiments are part of the embodiments of the present invention, rather than all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0037] A landiolol hydrochloride lyophilized powder for injection comprises landiolol hydrochloride, mannitol and a pH regulator, wherein the ratio of landiolol hydrochloride to mannitol is 1:0.8 to 1:1.2, preferably 1:1.

[0038] The freeze-dried powder injection also includes solvent water for injection, which is removed by sublimation during the drying process.

[0039] Generally speaking, the mass of the main drug landiolol hydrochloride contained in each vial of landiolol hydrochloride for injection is 50 mg, and the amount of the solvent water for injection used can be adjusted according to actual conditions, such as 3.5 ml / mg, 2.0 ml / mg or 1.0 ml / mg.

[0040] In the landiolol hydrochloride lyophilized powder for injection, the pH regulator is a sodium hydroxide solution with a concentration of 0.05 mol / L. Local pH that is too high or too low will cause landiolol hydrochloride to hydrolyze. Using a lower concentration of sodium hydroxide solution as a pH regulator can slow down the pH fluctuation generated during addition and avoid hydrolysis of landiolol hydrochloride.

[0041] A method for preparing landiolol hydrochloride lyophilized powder for injection comprises the following steps:

[0042] S1. Liquid preparation

[0043] Dissolve the prescribed amount of mannitol with part of the injection water, add the prescribed amount of landiolol hydrochloride and continue stirring to dissolve, adjust the pH value to 6.1±0.1 with a pH adjuster, and add the full amount of injection water; filter and fill the injection, and send it into a freeze-drying box after half-stoppering;

[0044] S2. Freeze-drying

[0045] The freeze-drying box is pre-freezing, and the product temperature is kept below -45°C, and the vacuum pump is started for primary and secondary drying. After drying, the plug is pressed out of the box to obtain the landiolol hydrochloride lyophilized powder for injection.

[0046] The step S1 specifically includes the following steps:

[0047] S11, dissolving mannitol with 80% of the prescribed amount of water for injection, controlling the temperature at 10-25° C., to obtain solution I;

[0048] S12, adding landiolol hydrochloride to solution I to dissolve, controlling the temperature at 10-25° C., to obtain solution II;

[0049] S13, adjust the pH value of solution II to 6.1±0.1 with 0.05 mol / L sodium hydroxide solution, stir for 10±2 min, add full amount of water for injection, and after stirring, filter with a 0.45 μm microporous filter and then fine filter with a 0.22 μm microporous filter to obtain solution III;

[0050] S14. Fill solution III into a 10 ml neutral silicone tube injection bottle, half-stopper it with a rubber stopper, and then send it into the freeze-drying box.

[0051] In the steps S11 and S13, the temperature of the water for injection is controlled at 10-25°C;

[0052] In the step S14, the rubber stopper is an ethylene tetrafluoroethylene copolymer film chlorinated butyl rubber stopper.

[0053] It should be noted that during the entire liquid preparation process of step S1, the liquid preparation temperature must not exceed 20° C. Peripheral cooling may be added during the liquid preparation process, such as circulating cold brine, to ensure that the temperature is controllable.

[0054] The step S2 specifically includes the following steps:

[0055] S21, pre-freezing

[0056] Install solution III in the machine for pre-freezing, set the refrigeration temperature of the partition to -45°C, keep the product temperature below -45°C, and then refrigerate the water trap to -45°C±1°C; turn on the vacuum pump, and start heating and sublimation when the vacuum degree in the freeze-drying box reaches 20Pa;

[0057] S22, one-step drying

[0058] Set the partition temperature to -15°C and start heating sublimation; after the partition temperature reaches -15°C, continue drying at this temperature for 15 to 45 hours;

[0059] S23, one-step drying

[0060] Set the partition temperature to 45°C, continue heating to remove bound water, and continue to keep warm and dry for 2 to 6 hours after reaching 45°C;

[0061] S24, full pressure plug

[0062] After the product is freeze-dried, fill the box with nitrogen to a pressure of -0.04MPa~-0.01MPa, turn off the nitrogen, balance for 10 minutes, and then press the full plug button to start the full plug process. Repeat the plugging twice, raise the shelf, open the freeze dryer air valve to balance the pressure of the box to normal pressure, and start unpacking.

[0063] During the primary drying, the partition temperature rises from -45°C to -15°C within 60 minutes; during the secondary drying, the partition temperature rises from -15°C to 45°C within 120 minutes.

[0064] During the secondary drying process, the vacuum is controlled at 10Pa to 30Pa by means of air permeation.

[0065] It should be emphasized that equipment confirmation is required before the freeze-drying process is operated, and the circulating water pressure must be controlled to be ≥0.05MPa, compressed air ≥0.4MPa, and nitrogen pressure ≥0.5MPa; turn on the freeze dryer power switch and preheat the compressor.

[0066] In order to ensure the freeze-drying effect and the stability of the freeze-dried powder injection, the freeze dryer is pre-cooled before filling, and the freeze dryer shelf temperature is reduced to 5℃~10℃; the sample is transferred to the freeze dryer at the same time as filling. During the entire filling process, the temperature of the freeze dryer shelf is kept below 10℃ until the filling is completed.

[0067] The present invention will be further described in detail below through specific implementation modes, but these specific implementation modes do not constitute any limitation to the present invention.

[0068] In the following examples, the raw material landiolol hydrochloride used is produced by Lanxiha Sanlian Pharmaceutical Co., Ltd., and the purity of landiolol hydrochloride is >99.0%; mannitol and sodium hydroxide are both pharmaceutical grade excipients.

[0069] Examples 1 to 3 can be used to compare the effects of different amounts of water for injection on the quality of the preparation.

[0070] Example 1

[0071] A landiolol hydrochloride lyophilized powder for injection, the prescription is:

[0072]

[0073] The preparation method of the landiolol hydrochloride lyophilized powder for injection comprises the following steps:

[0074] S1. Liquid preparation

[0075] S11, dissolving the prescribed amount of mannitol with 80% of the prescribed amount of water for injection to obtain solution I;

[0076] S12, adding the prescribed amount of landiolol hydrochloride into solution I to dissolve, to obtain solution II;

[0077] S13, adjust the pH value of solution II to 6.1±0.1 with 0.05 mol / L sodium hydroxide solution, stir for 10 min, add full amount of water for injection, and after stirring, filter with a 0.45 μm microporous filter and then fine filter with a 0.22 μm microporous filter to obtain solution III;

[0078] S14. Control the filling volume to 3.5-3.8 ml, fill solution III into a 10 ml colorless neutral silicone tube injection bottle, half-stopper it with a rubber stopper and send it into the freeze-drying box.

[0079] The temperature of the liquid preparation process is controlled at 10-25℃ throughout.

[0080] S2. Freeze-drying

[0081] S21. Equipment confirmation

[0082] Before the freeze-drying process is operated, the equipment must be confirmed to control the circulating water pressure ≥0.05MPa, the compressed air ≥0.4MPa, and the nitrogen pressure ≥0.5MPa; turn on the freeze dryer power switch and preheat the compressor.

[0083] S22, precooling

[0084] Start the freeze-drying cooling program, lower the freeze dryer shelf temperature to 5℃~10℃, and keep the freeze dryer shelf temperature below 10℃ during the entire filling process until the filling is completed;

[0085] S23, pre-freezing

[0086] Solution III was pre-frozen in the machine, the refrigeration temperature of the partition was set to -45°C, and the pre-freezing time was 360 minutes; after the pre-freezing, the water trap was cooled down, and when the temperature of the water trap reached -46°C, the vacuum pump was turned on, and when the dry box vacuum was 20Pa, heating sublimation began;

[0087] S24, one-step drying

[0088] The temperature of the partition was raised to -15°C within 60 min, and then the drying was continued at this temperature for 2700 min until the program was completed;

[0089] S25, secondary drying

[0090] The temperature of the partition is raised to 45°C within 120 minutes, and then continues to run at this temperature for 300 minutes until the program ends; during the secondary drying process, the vacuum is controlled at 10Pa to 30Pa by air permeation;

[0091] S26, full pressure plug

[0092] After the product is freeze-dried, fill the box with nitrogen to -0.04MPa~-0.01MPa, turn off the nitrogen, balance for 10 minutes, and then press the full plug button to start the full plug process. Repeat the plugging twice, raise the shelf, open the freeze dryer air valve to balance the pressure of the box to normal pressure, and start unpacking.

[0093] Example 2

[0094] A lyophilized powder of landiolol hydrochloride for injection, the prescription is

[0095]

[0096] The preparation method of landiolol hydrochloride lyophilized powder for injection comprises the following steps:

[0097] S1. Liquid preparation

[0098] S11, dissolving the prescribed amount of mannitol with 80% of the prescribed amount of water for injection to obtain solution I;

[0099] S12, adding the prescribed amount of landiolol hydrochloride into solution I to dissolve, to obtain solution II;

[0100] S13, adjust the pH value of solution II to 6.1±0.1 with 0.05 mol / L sodium hydroxide solution, stir for 10 min, add full amount of water for injection, and after stirring, filter with a 0.45 μm microporous filter and then fine filter with a 0.22 μm microporous filter to obtain solution III;

[0101] S14. Control the filling volume to 2.0-2.2 ml, fill solution III into a 10 ml colorless neutral silicone tube injection bottle, half-stopper it with a rubber stopper and send it into the freeze-drying box.

[0102] The temperature of the liquid preparation process is controlled at 10-25℃ throughout.

[0103] S2. Freeze-drying

[0104] S21. Before the freeze-drying process is operated, the equipment must be confirmed to control the circulating water pressure ≥0.05MPa, the compressed air ≥0.4MPa, and the nitrogen pressure ≥0.5MPa; turn on the freeze dryer power switch and preheat the compressor.

[0105] S22, start the freeze-drying cooling program, reduce the shelf temperature of the freeze dryer to 5°C to 10°C, and keep the shelf temperature of the freeze dryer below 10°C during the entire filling process until the filling is completed;

[0106] S23, pre-freezing

[0107] Solution III was pre-frozen in the machine, the partition refrigeration temperature was set to -45°C, and the pre-freezing time was 240 min. After the pre-freezing, the water trap was cooled down, and when the water trap temperature reached -46°C, the vacuum pump was turned on, and when the dry box vacuum reached 20Pa, heating and sublimation began.

[0108] S24, one-step drying

[0109] The temperature of the partition was raised to -15°C within 60 min, and then the drying was continued at this temperature for 1600 min until the program was completed.

[0110] S25, secondary drying

[0111] The temperature of the partition is raised to 45°C within 120 minutes, and then continues to operate at this temperature for 240 minutes until the program ends. During the secondary drying process, the vacuum is controlled at 10Pa to 30Pa by gas permeation;

[0112] S26, full pressure plug

[0113] After the product is freeze-dried, fill the box with nitrogen to -0.04MPa~-0.01MPa, turn off the nitrogen, balance for 10 minutes, and then press the full plug button to start the full plug process. Repeat the plugging twice, raise the shelf, open the freeze dryer air valve to balance the pressure of the box to normal pressure, and start unpacking.

[0114] Example 3

[0115] A landiolol hydrochloride lyophilized powder for injection, the prescription is:

[0116]

[0117] The preparation method of landiolol hydrochloride lyophilized powder for injection comprises the following steps:

[0118] S1. Liquid preparation

[0119] S11, dissolving the prescribed amount of mannitol with 80% of the prescribed amount of water for injection to obtain solution I;

[0120] S12, adding the prescribed amount of landiolol hydrochloride into solution I to dissolve, to obtain solution II;

[0121] S13, adjust the pH value of solution II to 6.1±0.1 with 0.05 mol / L sodium hydroxide solution, stir for 10 min, add full amount of water for injection, and after stirring, filter with a 0.45 μm microporous filter and then fine filter with a 0.22 μm microporous filter to obtain solution III;

[0122] S14. Control the filling volume to 1.0ml~1.1ml, fill solution III into a 10ml colorless neutral silicone tube injection bottle, half-stopper it with ethylene tetrafluoroethylene film rubber stopper and send it into the freeze drying box.

[0123] The temperature of the liquid preparation process is controlled at 10-25℃ throughout.

[0124] S2. Freeze-drying

[0125] S21. Equipment confirmation

[0126] Before the freeze-drying process is operated, the equipment must be confirmed to control the circulating water pressure ≥0.05MPa, the compressed air ≥0.4MPa, and the nitrogen pressure ≥0.5MPa; turn on the freeze dryer power switch and preheat the compressor.

[0127] S22, precooling

[0128] Start the freeze-drying cooling program, lower the freeze dryer shelf temperature to 5℃~10℃, and keep the freeze dryer shelf temperature below 10℃ during the entire filling process until the filling is completed;

[0129] S23, pre-freezing

[0130] Solution III was pre-frozen in the machine, the refrigeration temperature of the partition was set to -45°C, and the pre-freezing time was 180 minutes; after the pre-freezing, the water trap was cooled down, and when the temperature of the water trap reached -46°C, the vacuum pump was turned on, and when the dry box vacuum was 20Pa, heating sublimation began;

[0131] S24, one-step drying

[0132] The temperature of the partition was raised to -15°C within 60 min, and then the drying was continued at this temperature for 900 min until the program was completed.

[0133] S25, secondary drying

[0134] The temperature of the partition is raised to 45°C within 120 minutes, and then continues to operate at this temperature for 180 minutes until the program ends; during the secondary drying process, the vacuum is controlled at 10Pa to 30Pa by air permeation;

[0135] S26, full pressure plug

[0136] After the product is freeze-dried, fill the box with nitrogen to -0.04MPa~-0.01MPa, turn off the nitrogen, balance for 10 minutes, and then press the full plug button to start the full plug process. Repeat the plugging twice, raise the shelf, open the freeze dryer air valve to balance the pressure of the box to normal pressure, and start unpacking.

[0137] The freeze-dried powder injections prepared in Examples 1, 2 and 3 were tested for formulation, and the original formulation of landiolol hydrochloride for injection (batch number: 2366YB) marketed in Japan and produced by Ono Pharmaceutical Industries, Ltd. was used as Comparative Example 1.

[0138] The detection method is high performance liquid chromatography (Chinese Pharmacopoeia 2020 Edition Part IV General Rules 0512). The specific detection method is: use octadecylsilane bonded silica gel as a filler (shim-pack GIST C18, 4.6×250mm, 5μm or a chromatographic column with equivalent performance); use phosphate buffer (take 5.44g of potassium dihydrogen phosphate, add 1000ml of water to dissolve, and adjust the pH value to 6.5 with 40% potassium hydroxide solution)-acetonitrile (70:30) as mobile phase A, and acetonitrile as mobile phase B; the flow rate is 1.0ml / min; the column temperature is 35°C; the sample chamber temperature is 5°C; the detection wavelength is 220nm; the injection volume is 20μl; and gradient elution is performed according to the following table:

[0139]

[0140] The test results are shown in the table below.

[0141]

[0142] It can be seen from the test data in the above table that the properties of the three examples meet the requirements, and the properties of Examples 2 and 3 are better than those of Example 1, and the property of Example 3 is the best. The total impurities and product contents of the related substances of the preparations of Examples 1 to 3 meet the standard requirements, among which the related substances of the preparation of Example 3 are significantly better than the original preparation in the high temperature 60°C test, and the related substances of Examples 1 and 2 are basically equivalent to the original preparation.

[0143] In the investigation of influencing factors (60°C), the total impurities of related substances in the preparations of Examples 1 to 3 all increased, and the growth trend was consistent, and the content gradually decreased over time. This shows that this product is relatively sensitive to temperature.

[0144] It can be seen from the test results of the preparations of Examples 1 to 3 that within a certain control range, the different amounts of solvents have little effect on the quality of freeze-dried powder injection preparations. The registration batches are different according to the different amounts of solvents, which means different raw material costs, different freeze-drying times, and different corresponding energy consumption. The appropriate concentration of the solution can be selected according to the actual situation of the factory.

[0145] The original formulation of landiolol hydrochloride for injection marketed in Japan, which does not adopt the technical solution of the present invention, was used as comparative example 1, and compared with the landiolol hydrochloride for injection prepared in Example 3 of the present invention, and the accelerated test was performed at a temperature of 40° C. and a relative humidity of 75% for 3 months, and the stability test was performed at a temperature of 25° C. and a relative humidity of 60%. The test results are shown in the table below.

[0146]

[0147] It can be seen from the test data in the above table that the relevant substances of the landiolol hydrochloride lyophilized powder for injection in Example 3 of the present invention are significantly better than those of the original preparation, and the other quality conditions are basically the same as the reference preparation. There is basically no change in the properties during the stability study, indicating that the landiolol hydrochloride for injection using the technical solution of the present invention still has good stability under long-term storage conditions. In addition, the results of the embodiment product when inverted and upright are not much different, indicating that it has good compatibility with the rubber plug.

[0148] Examples 4 to 6 are used to compare the effects of different preparation temperatures on the quality of the preparation intermediate drug solution.

[0149] Example 4

[0150] prescription:

[0151]

[0152]

[0153] The preparation process is:

[0154] The temperature was controlled at 2-8°C throughout the process. The prescribed amount of mannitol was added to 80% of the prescribed amount of water for injection, stirred to dissolve, and then the prescribed amount of landiolol hydrochloride was added, stirred to dissolve, and the pH value was adjusted to 6.1±0.1 with 0.05mol / L sodium hydroxide solution. After adding the full amount of water for injection and stirring, the mixture was filtered with 0.45μm and 0.22μm filter membranes to obtain the drug solution to be investigated. The storage time limit of the drug solution was 24h.

[0155] Example 5

[0156] prescription:

[0157]

[0158] The preparation process is:

[0159] The temperature was controlled at 20℃±5℃ throughout the process. The prescribed amount of mannitol was added to 80% of the prescribed amount of water for injection, stirred to dissolve, and then the prescribed amount of landiolol hydrochloride was added, stirred to dissolve, and the pH value was adjusted to 6.1±0.1 with 0.05mol / L sodium hydroxide solution. After adding the full amount of water for injection and stirring, the mixture was filtered with 0.45μm and 0.22μm filter membranes to obtain the drug solution to be investigated. The storage time limit of the drug solution was 24h.

[0160] Example 6

[0161] prescription:

[0162]

[0163] The preparation process is:

[0164] The temperature was controlled at 35℃±5℃ throughout the process. The prescribed amount of mannitol was added to 80% of the prescribed amount of water for injection, stirred to dissolve, and then the prescribed amount of landiolol hydrochloride was added, stirred to dissolve, and the pH value was adjusted to 6.1±0.1 with 0.05mol / L sodium hydroxide solution. After adding the full amount of water for injection and stirring, it was filtered with 0.45μm and 0.22μm filter membranes to obtain the drug solution to be investigated. The storage time limit of the drug solution was 24h.

[0165] The drug solutions prepared in Example 4, Example 5 and Example 6 were tested, and the properties, pH value and total impurities of the drug solutions were tested at 0 h, 18 h and 24 h, respectively, to compare the effects of different preparation temperatures of the semi-finished drug solution on the quality of the drug solution of the preparation intermediate.

[0166] The test data is shown in the table below.

[0167]

[0168] It can be seen from the test data in the above table that under the three preparation temperature conditions, the contents of related substances in the liquid at the moment of preparation (i.e. 0h) are 0.23%, 0.23%, and 0.26%, respectively, with little difference; when placed under the preparation conditions of 2-8℃ for 18h and 24h, the properties, pH value, and related substances of the liquid are basically unchanged, which shows that the semi-finished liquid of this product has good stability within 24h under the conditions of ≤8℃. The liquid of Example 5 is placed under the conditions of 20±5℃ for 18h and above, and the related substances increase to a certain extent; the liquid of Example 6 is placed under the conditions of 35±5℃, and as the placement time increases, the related substances increase significantly, and the quality of the liquid changes significantly, which does not meet the quality requirements. According to the test data, the intermediate liquid of this product is more sensitive to temperature, and the preparation temperature should be controlled under the conditions of ≤25℃. If the liquid needs to be placed for a long time, the preparation temperature needs to be further reduced.

[0169] Since low-temperature liquid preparation consumes more energy and the dissolution time of auxiliary materials is prolonged, based on comprehensive consideration of multiple factors, it is more appropriate to select a liquid preparation temperature of 10-25°C, and the liquid preparation process should be controlled within 8 hours.

[0170] Examples 7 and 8 are used to compare the effects of different mannitol dosages on the quality of the preparations.

[0171] Example 7

[0172] A landiolol hydrochloride lyophilized powder for injection, the prescription is:

[0173]

[0174] The preparation method of landiolol hydrochloride lyophilized powder for injection comprises the following steps:

[0175] S1. Liquid preparation

[0176] S11, dissolving the prescribed amount of mannitol with 80% of the prescribed amount of water for injection to obtain solution I;

[0177] S12, adding the prescribed amount of landiolol hydrochloride into solution I to dissolve, to obtain solution II;

[0178] S13, adjust the pH value of solution II to 6.1±0.1 with 0.05 mol / L sodium hydroxide solution, stir for 10 min, add full amount of water for injection, and after stirring, filter with a 0.45 μm microporous filter and then fine filter with a 0.22 μm microporous filter to obtain solution III;

[0179] S14. Control the filling volume to 1.0ml~1.1ml, fill solution III into a 10ml colorless neutral silicone tube injection bottle, half-stopper it with ethylene tetrafluoroethylene film rubber stopper and send it into the freeze drying box.

[0180] The temperature of the liquid preparation process is controlled at 10-25℃ throughout.

[0181] S2. Freeze-drying

[0182] S21. Equipment confirmation

[0183] Before the freeze-drying process is operated, the equipment must be confirmed to control the circulating water pressure ≥0.05MPa, the compressed air ≥0.4MPa, and the nitrogen pressure ≥0.5MPa; turn on the freeze dryer power switch and preheat the compressor.

[0184] S22, precooling

[0185] Start the freeze-drying cooling program, lower the freeze dryer shelf temperature to 5℃~10℃, and keep the freeze dryer shelf temperature below 10℃ during the entire filling process until the filling is completed;

[0186] S23, pre-freezing

[0187] Solution III was pre-frozen in the machine, the refrigeration temperature of the partition was set to -45°C, and the pre-freezing time was 180 minutes; after the pre-freezing, the water trap was cooled down, and when the temperature of the water trap reached -46°C, the vacuum pump was turned on, and when the dry box vacuum was 20Pa, heating sublimation began;

[0188] S24, one-step drying

[0189] The temperature of the partition was raised to -15°C within 60 min, and then the drying was continued at this temperature for 900 min until the program was completed.

[0190] S25, secondary drying

[0191] The temperature of the partition is raised to 45°C within 120 minutes, and then continues to operate at this temperature for 180 minutes until the program ends; during the secondary drying process, the vacuum is controlled at 10Pa to 30Pa by air permeation;

[0192] S26, full pressure plug

[0193] After the product is freeze-dried, fill the box with nitrogen to -0.04MPa~-0.01MPa, turn off the nitrogen, balance for 10 minutes, and then press the full plug button to start the full plug process. Repeat the plugging twice, raise the shelf, open the freeze dryer air valve to balance the pressure of the box to normal pressure, and start unpacking.

[0194] Example 8

[0195] A landiolol hydrochloride lyophilized powder for injection, the prescription is:

[0196]

[0197] The preparation method of landiolol hydrochloride lyophilized powder for injection comprises the following steps:

[0198] S1. Liquid preparation

[0199] S11, dissolving the prescribed amount of mannitol with 80% of the prescribed amount of water for injection to obtain solution I;

[0200] S12, adding the prescribed amount of landiolol hydrochloride into solution I to dissolve, to obtain solution II;

[0201] S13, adjust the pH value of solution II to 6.1±0.1 with 0.05 mol / L sodium hydroxide solution, stir for 10 min, add full amount of water for injection, and after stirring, filter with a 0.45 μm microporous filter and then fine filter with a 0.22 μm microporous filter to obtain solution III;

[0202] S14. Control the filling volume to 1.0ml~1.1ml, fill solution III into a 10ml colorless neutral silicone tube injection bottle, half-stopper it with ethylene tetrafluoroethylene film rubber stopper and send it into the freeze drying box.

[0203] The temperature of the liquid preparation process is controlled at 10-25℃ throughout.

[0204] S2. Freeze-drying

[0205] S21. Equipment confirmation

[0206] Before the freeze-drying process is operated, the equipment must be confirmed to control the circulating water pressure ≥0.05MPa, the compressed air ≥0.4MPa, and the nitrogen pressure ≥0.5MPa; turn on the freeze dryer power switch and preheat the compressor.

[0207] S22, precooling

[0208] Start the freeze-drying cooling program, lower the freeze dryer shelf temperature to 5℃~10℃, and keep the freeze dryer shelf temperature below 10℃ during the entire filling process until the filling is completed;

[0209] S23, pre-freezing

[0210] Solution III was pre-frozen in the machine, the refrigeration temperature of the partition was set to -45°C, and the pre-freezing time was 180 minutes; after the pre-freezing, the water trap was cooled down, and when the temperature of the water trap reached -46°C, the vacuum pump was turned on, and when the dry box vacuum was 20Pa, heating sublimation began;

[0211] S24, one-step drying

[0212] The temperature of the partition was raised to -15°C within 60 min, and then the drying was continued at this temperature for 900 min until the program was completed.

[0213] S25, secondary drying

[0214] The temperature of the partition is raised to 45°C within 120 minutes, and then continues to operate at this temperature for 180 minutes until the program ends; during the secondary drying process, the vacuum is controlled at 10Pa to 30Pa by air permeation;

[0215] S26, full pressure plug

[0216] After the product is freeze-dried, fill the box with nitrogen to -0.04MPa~-0.01MPa, turn off the nitrogen, balance for 10 minutes, and then press the full plug button to start the full plug process. Repeat the plugging twice, raise the shelf, open the freeze dryer air valve to balance the pressure of the box to normal pressure, and start unpacking.

[0217] Comparative Example 2

[0218] This comparative example is the comparative example of Example 3, and the preparation method is exactly the same, except that the usage ratio of landiolol hydrochloride to mannitol in this comparative example is 1:0.7. The specific prescription is:

[0219]

[0220]

[0221] Comparative Example 3

[0222] This comparative example is the comparative example of Example 3, and the preparation method is exactly the same, except that the usage ratio of landiolol hydrochloride to mannitol in this comparative example is 1:1.3. The specific prescription is:

[0223]

[0224] The freeze-dried powder injections prepared in Example 3, Example 7, Example 8, Comparative Example 2, and Comparative Example 3 were subjected to preparation testing to compare the effects of different mannitol dosages on the preparation quality.

[0225] According to the high performance liquid chromatography method (General Rules 0512 of Part IV of the Chinese Pharmacopoeia 2020 Edition), the relevant substances and contents were determined, and the osmotic pressure was tested (General Rules 0632 of Part IV of the Chinese Pharmacopoeia 2020 Edition). The experimental results are shown in the table below.

[0226]

[0227]

[0228] It can be seen from the test data in the above table that when the ratio of landiolol hydrochloride to mannitol is in the range of 1:0.8 to 1:1.2, the appearance of the product is good, the total impurity content of related substances is within the controllable range within 30 days, the product meets the quality requirements, the osmotic pressure molar concentration is controlled at 210 to 245 mOsmol / kg, and the properties are white loose lumps. Different mannitol dosages affect the osmotic pressure molar concentration and properties of the preparation. When the dosage of mannitol is increased or decreased, the osmotic pressure molar concentration of Comparative Example 2 is low and the osmotic pressure molar concentration of Comparative Example 3 is too high, which leads to obvious shrinkage or cracking of the drug properties, which does not meet the quality requirements.

[0229] Comparative Examples 4 to 7 are used to compare the effect of the pH value of the drug solution on the quality of the preparation.

[0230] Comparative Example 4

[0231] This comparative example is a comparative example of Example 3, and the prescription and preparation method are exactly the same, except that the pH value of the semi-finished drug solution in this comparative example is controlled at 5.7±0.1.

[0232] Comparative Example 5

[0233] This comparative example is a comparative example of Example 3, and the prescription and preparation method are exactly the same, except that the pH value of the semi-finished drug solution in this comparative example is controlled at 6.5±0.1.

[0234] Comparative Example 6

[0235] This comparative example is a comparative example of Example 3, and the prescription and preparation method are exactly the same, except that the pH value of the semi-finished drug solution in this comparative example is controlled at 6.4±0.1.

[0236] Comparative Example 7

[0237] This comparative example is a comparative example of Example 3, and the prescription and preparation method are exactly the same, except that the pH value of the semi-finished drug solution in this comparative example is controlled at 5.8±0.1.

[0238] According to the high performance liquid chromatography method (General Rules 0512 of Part IV of the Chinese Pharmacopoeia 2020 Edition), the relevant substances and contents were determined, and the osmotic pressure was tested (General Rules 0632 of Part IV of the Chinese Pharmacopoeia 2020 Edition). The experimental results are shown in the table below.

[0239]

[0240]

[0241] From the test data in the above table, it can be seen that the semi-finished product pH value is too high or too low, which will have a great impact on the product quality. This may be because the pH value is too high or too low, which promotes the hydrolysis of the main component, thereby producing too many impurities. From the comparative data, it can be seen that the low pH value (Comparative Example 4, pH 5.7) has a greater impact on the product quality, and the content of related substances after 30 days is higher.

[0242] Comparative Example 6 controls the pH value to 6.3, and Comparative Example 7 controls the pH value to 5.8. The product quality is similar and better than Comparative Example 4 and Comparative Example 5. However, compared with Example 3 where the pH value is controlled to 6.1±0.1, the content of related substances is significantly increased. Therefore, controlling the pH value of this product to 6.1±0.1 is beneficial to the long-term storage of the product.

[0243] The above description is only a preferred embodiment of the present invention. All equivalent changes and modifications made according to the scope of the patent application of the present invention should fall within the scope of the present invention.

Claims

1. A landiolol hydrochloride lyophilized powder for injection, characterized in that: The invention comprises landiolol hydrochloride, mannitol and a pH regulator, wherein the mass ratio of the landiolol hydrochloride to the mannitol is 1:0.8 to 1:1.

2.

2. The landiolol hydrochloride lyophilized powder for injection according to claim 1, characterized in that: The pH regulator is a sodium hydroxide solution with a concentration of 0.05 mol / L.

3. The landiolol hydrochloride lyophilized powder for injection according to any one of claims 1 or 2, characterized in that: Each vial of landiolol hydrochloride injection contains 50 mg of the main drug landiol hydrochloride.

4. A method for preparing the landiolol hydrochloride lyophilized powder for injection as claimed in any one of claims 1 to 3, characterized in that The following steps are involved: S1. Liquid preparation Dissolve the prescribed amount of mannitol with part of the injection water, add the prescribed amount of landiolol hydrochloride and continue stirring to dissolve, adjust the pH value to 6.1±0.1 with a pH adjuster, and add the full amount of injection water; filter and fill the injection, and send it into a freeze-drying box after half-stoppering; S2. Freeze-drying The freeze-drying box is pre-freezing, and the product temperature is kept below -45°C, and the vacuum pump is started for primary and secondary drying. After drying, the plug is pressed out of the box to obtain the landiolol hydrochloride lyophilized powder for injection.

5. The method for preparing the landiolol hydrochloride lyophilized powder for injection according to claim 4, characterized in that: The step S1 specifically includes the following steps: S11, dissolving mannitol with 80% of the prescribed amount of water for injection, controlling the temperature at 10-25° C., to obtain solution I; S12, adding landiolol hydrochloride to solution I to dissolve, controlling the temperature at 10-25° C., to obtain solution II; S13, adjust the pH value of solution II to 6.1±0.1 with 0.05 mol / L sodium hydroxide solution, stir for 10±2 min, add full amount of water for injection, and after stirring, filter with a 0.45 μm microporous filter and then fine filter with a 0.22 μm microporous filter to obtain solution III; S14. Fill solution III into a 10 ml neutral silicone tube injection bottle, half-stopper it with a rubber stopper, and then send it into the freeze-drying box.

6. The method for preparing the landiolol hydrochloride lyophilized powder for injection according to claim 5, characterized in that: The liquid preparation temperature in step S1 does not exceed 25° C.; the rubber stopper is an ethylene tetrafluoroethylene copolymer film chlorinated butyl rubber stopper.

7. The method for preparing the landiolol hydrochloride lyophilized powder for injection according to claim 4, characterized in that: The step S2 specifically includes the following steps: S21, pre-freezing Install solution III in the machine for pre-freezing, set the refrigeration temperature of the partition to -45°C, keep the product temperature below -45°C, and then refrigerate the water trap to -45°C±1°C; turn on the vacuum pump, and start heating and sublimation when the vacuum degree in the freeze-drying box reaches 20Pa; S22, one-step drying Set the partition temperature to -15°C and start heating sublimation; after the partition temperature reaches -15°C, continue drying at this temperature for 15 to 45 hours; S23, secondary drying Set the partition temperature to 45°C, continue heating to remove bound water, and continue to keep warm and dry for 2 to 6 hours after reaching 45°C; S24, full pressure plug After the product is freeze-dried, fill the box with nitrogen to -0.04MPa~-0.01MPa, turn off the nitrogen, balance for 10 minutes, and then press the full plug button to start the full plug process. Repeat the plugging twice, raise the shelf, open the freeze dryer air valve to balance the pressure of the box to normal pressure, and start unpacking.

8. The method for preparing the landiolol hydrochloride lyophilized powder for injection according to claim 7, characterized in that: During the primary drying, the partition temperature rises from -45°C to -15°C within 60 minutes; during the secondary drying, the partition temperature rises from -15°C to 45°C within 120 minutes.

9. The method for preparing the landiolol hydrochloride lyophilized powder for injection according to claim 7, characterized in that: During the secondary drying process, the vacuum is controlled at 10Pa to 30Pa by means of air permeation.

Citation Information

Cited By

  • Vancomycin hydrochloride for injection and preparation method thereof

    CN121648254A